InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,101.24
(
-0.29%
)
US TECH 100
21,156.80
(
-0.70%
)
Dow Jones
44,424.25
(
-0.32%
)
Brent Oil
77.63
(
0.00%
)
Bitcoin
104,952.92
(
0.21%
)
Post# of 672433
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Lady-baron

Send PM Follow Ignore
Followers 15
Posts 1594
Boards Moderated 0
Alias Born 07/22/2005

Lady-baron

Re: Lady-baron post# 299529

Monday, 03/10/2014 8:26:49 AM

Monday, March 10, 2014 8:26:49 AM

Post# of 672433
RGDX. to Offer Expanded KRAS Mutation Test to Improve Treatment Decisions for Colorectal Cancer Patients

As a company known for its first-to-market innovation, we are pleased to introduce a test that detects more mutations in a gene not examined previously, allowing for a more thorough and comprehensive screening of colorectal cancer," said Thomas A. Bologna, Chairman and Chief Executive Officer of Response Genetics. "Identifying a broader range of KRAS mutations increases the potential for more targeted and appropriate treatment of colorectal cancer patients
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up